Effects of Mangosteen pericarp Extract to Clinical Improvements, The Plasma Level of IL-6 and Malondialdehyde in Acute Exacerbation of COPD Patients
DOI:
https://doi.org/10.36497/jri.v38i3.6Keywords:
mangosteen pericarp extract, acute exacerbation of COPD, clinical improvements, plasma level of IL-6, plasma level of MDAAbstract
Background: Amplification of inflammation in acute exacerbation of chronic obstructive pulmonary disease (COPD) increases inflammatory mediators and oxidative stress in the airways, pulmonary and systemic circulation that are characterized by increased plasma level of IL-6 and MDA, resulting in worsening of clinical symptoms. Xanthones in mangosteen pericarp have anti-inflammatory and antioxidant effects, potentially as an adjuntive therapy in acute exacerbations of COPD. Methods: The aim of this study was to determine the effect of mangosteen pericarp extract to clinical improvements, plasma level of IL-6 and MDA of acute exacerbation COPD patients. A clinical trial of experimental with pretest and posttest was conducted on 34 acute exacerbation of COPD patients in Dr. Moewardi Hospital Surakarta and Dr. Ario Wirawan Lung Hospital Salatiga from April until May 2016. The sample was taken by consecutive sampling. Subjects were divided by randomized double blind technique into the treatment group (n=17) received mangosteen pericarp extract 2x1100mg/day and control group (n = 17) received placebo. Clinical improvements were measured in CAT score and length of stay. CAT score, plasma level of IL-6 and MDA were measured on admission and at discharge. Length of stay based on the number of days of care in hospitals. Results: There was significant difference (p=0,011) towards decreased of IL-6 plasma level between treatment group (-2,17 ± 3,46 pg/ mL) and control group (+1,67 ± 6,81 pg/mL). There were no significant difference towards decreased of length of stay (p=0,34) between treatment group (4,12 ± 1,54 days) and control group (5,24 ± 2,49 days), towards decreased of CAT score (p=0,252) between treatment group (-19,18 ± 3,96) and control group (-18,24 ± 2,75), and towards decreased of MDA plasma level (p=0,986) between treatment group (+0,03 ± 0,36μmol/L) and control group (+0,35 ± 1,58). Conclusions: The addition of mangosteen pericarp extract 2x1100mg/day during hospitalization was significantly lowered plasma levels of IL-6, but were not significant in lowering the CAT score, shortening the length of stay, and reducing the increase in plasma level of MDA.Downloads
References
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease update 2015. [Internet]. 2015 [Cited 2016 January 15]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf.
Donaldson GC, Wedzicha JA. COPD exacerbation 1: epidemiology. Thorax. 2006;61:164-8.
Samy N, Matsoud A, Khayyal AE, Imam A. Cinical utility of biomarkers as predictors of lung function in chronic obstructive pulmonary disease. New York Science Journals. 2010. [Internet]. [Cited 2015 September 25th]. Available from: http://www.sciencepub.net/newyork.
Ferrari R, Tanni SE, Caram LMO, Corrêa C, Corrêa CR, Godoy I. Three-year follow-up of interleukin-6 and c-reactive protein in chronic obstructive pulmonary disease. Respir Res2013;14:1-7.
Kubera J, Hammerman K, Williams CMM, Hubeau C. Interleukin-6 neutralization alleviates acute exacerbation-like disease in a model of cigarette smoke-induced pulmonary inflammation. J Inflamm. 2013;10:33.
Cavalcante AG, Brain PF. The role of oxidative stress in COPD: current concepts and perspectives. J Bras Pneumol. 2009;35:1227-37.
Roca M, Verduri A, Corbetta L, Clini B, Fabbri LM, Beghe B. Mechanism of acute exacerbations of respiratory symptoms in chronic obstructive pulmonary disease. Eur J ClinInvest. 2013;43:510-21.
Mackay A, Wedzicha J. Etiological factors in copd exacerbations. Annals of Respiratory medicine. [Internet]. 2011 [Cited 2016 January 25]. Available from: www.slim-respiratory.com.
Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev. 2013;12:543-59.
Pedraza J, Cardenas N, Orozco M, Perez JM. Medicinal properties of mangosteen (Garcinia mangostana). Food Chem Toxicol. 2008:3227-39.
Gutierrez F, failla ML. Biological activities and bioavailibility of mangosteen xanthones: a critical review of the current evidence. Nutrients. 2013;5:3163-83.
Ibrahim MY, Hashim NM, Mariod AA, Mohan S, Abdullah MA, Abdelwahab SI. α- Mangostin from Garcinia mangostana Linn: an update review of its pharmacological properties. Arabian J Chem. 2014:1-13.
Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respire Cell Mol Biol.2009;41:631-8.
Suradi. Sutanto YS, Reviono, Harsini, Mahendra D. Hubungan antara penyakit paru obstruktif kronik eksaserbasi akut dengan hasil kultur sputum bakteri pada rumah sakit dr. moewardi surakarta. J Respir Indo. 2012;l32:218-22.
Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8:1281-90.
Moraes MR, Costa AC, Correx KS, Kipnis APJ, Rabahi MF. Interleukin-6 and interleukin-8 blood level’s poor association with the severity and clinical profile of ex-smokers with copd. Int J Chron Obstruct Pulmon Dis. 2014;4:735-43.
Indrayati D. Peran curcumin terhadap kadar malondealdihyde plasma, kadar interleukin 6 plasma, skor COPD assesment test dan lama rawat inap penyakit paru obstruktif kronik eksaserbasi akut. Tesis Universitas Sebelas Maret. Surakarta; 2014.
Rahman I. Adcock IM. Oxidative stress and redox regulation of lung inflammation in copd. Eur Respir J. 2006;28:219–42.
Leonardi M. Hubungan kebiasaan merokok dengan timbulnya radikal bebas. Tesis Fakultas Kedokteran Universitas Sumatera Utara. Medan; 2013.
Singh Z, Karthigesu IP, Singh P, Kaur R. Use of malondialdehyde as a biomarker for assessing oxidative stress in different disease pathologies: a review. Iranian J Publ Health. 2014;43:7-16.
Perhimpunan Dokter Paru Indonesia. Penyakit paru obstruktif kronik (PPOK): Pedoman praktis dan penatalaksanaan di Indonesia. Jakarta: Indah Offset Grafika; 2016.p.1-88.
Downloads
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
